Japan Prevention Trial of Diabetes by Pitavastatin in Patients With Impaired Glucose Tolerance (J-PREDICT)

Exclusion Criteria

• •History of diabetes (except gestational diabetes)
• •Fasting plasma glucose \>= 126 mg/dl , and/or 2-h plasma glucose \>= 200 mg/dl
• •HbA1c \>= 6.5%
• •Diabetic retinopathy
• •Receiving with hormone replacement therapy
• •Pancreatic diseases ( e.g. pancreatitis, pancreatectomy, pancreatic cancer), Endocrine diseases ( e.g. Cushing's syndrome, acromegaly, pheochromocytoma, aldosteronism, hyperthyroidism )
• •Receiving statins, fibrates or anion exchange resins
• •Cancer or suspected cancer
• •History of gastrectomy
• •History of myocardial infarction, angina, or heart failure (NYHA Class \>= III)
• •Severe hypertension (SBP \>= 180 mmHg or DBP \>= 110 mmHg)
• •Renal disease, including serum creatinine \>= 2.0 mg/dl
• •Hepatic disease, including transaminase (ALT or AST) \>= 2 times the upper limit of normal
• •Women hoping to become pregnant during the intended study period
• •Contraindication or relative contraindication of Livalo® Tab(pitavastatin calcium)
• •1. History of hypersensitivity to any of the ingredients of the product
• •2. Severe hepatic disorder or biliary atresia
• •3. Receiving cyclosporine
• •4. Pregnant women, women suspected of being pregnant, or lactating women
• •5. Patients receiving fibrates who also have laboratory evidence of abnormal renal function
• •Familial hypercholesterolemia
• •Drug abuse, alcoholism
• •Individuals who are ineligible in the opinion of the investigator